Lotte Biologics Makes Headway on South Korean API Plant

---

Researched by Industrial Info Resources (Sugar Land, Texas)--Lotte Biologics (Seoul, South Korea) has signed a land sale contract to build a plant for the manufacture of active pharmaceutical ingredients (APIs) in Songdo International City, Incheon, South Korea.

Currently, design work is in progress with Lotte Engineering & Construction (Seoul), and it is expected that construction and subcontracting contracts will be issued after the first half of next year.

The facility will have a production capacity of 120,000 liters of antibody drugs when completed in 2027.

Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical-Biotech Project Database can click here for the project report.

Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 trillion (USD).